Boehringer Ingelheim and Lilly announced that Jentadueto (linagliptin/metformin) is now available as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. Jentadueto is a fixed-dose combination product containing linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Linagliptin increases the concentrations of active incretin hormones, which stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation. Metformin improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial glucose.
Jentadueto is available in 2.5mg/500mg, 2.5mg/850mg, and 2.5mg/1000mg dosage strength tablets and come in 60- and 180-count bottles.
For more information, call (800) 542-6257 or visit www.jentadueto.com.